Corporate Venture Capital Fund Profiles
For Reference of EnterpriseWorks Tenants

wirtz2
11/1/2013
VC Table of Contents

ABB Technology Ventures ..................................................................................................................................... 2
Abbvie Ventures .................................................................................................................................................... 2
Aster Capital .......................................................................................................................................................... 3
AMD Ventures ....................................................................................................................................................... 3
Amgen Ventures ................................................................................................................................................... 4
Astellas Venture Management ............................................................................................................................. 4
BASF Venture Capital ............................................................................................................................................. 5
Baxter Ventures .................................................................................................................................................... 6
Bloomberg Ventures ............................................................................................................................................. 6
Boehringer Ingelheim Ventures ............................................................................................................................ 7
Comcast Ventures ................................................................................................................................................ 7
CTV ........................................................................................................................................................................ 8
Dow Venture Capital ............................................................................................................................................... 9
Evonik Corporate Venturing .................................................................................................................................. 9
GE Ventures ......................................................................................................................................................... 10
GM Ventures ........................................................................................................................................................ 10
Google Ventures .................................................................................................................................................. 11
Hitachi Corporate Venture Capital Fund ................................................................................................................ 11
Intel Capital .......................................................................................................................................................... 12
Johnson and Johnson Development Corporation ................................................................................................. 13
Lilly Asia Ventures ............................................................................................................................................... 13
Lilly Ventures ...................................................................................................................................................... 14
Merck Research Venture Fund ............................................................................................................................. 14
Morgan Stanley Venture Partners ......................................................................................................................... 15
Motorola Solutions Venture Capital ..................................................................................................................... 15
Panasonic Venture Group .................................................................................................................................... 16
Pereg Ventures .................................................................................................................................................... 17
Pfizer Venture Investments .................................................................................................................................... 17
Samsung Ventures ................................................................................................................................................ 18
SR One (GlaxoSmithKline) .................................................................................................................................... 19
Takeda Ventures .................................................................................................................................................... 19
**ABB Technology Ventures (ATV)**

**Corporate Arm:** ABB  
**Website:** [http://www.abb.us/cawp/abbzh254/9cefb344ae2fbf87c1257918002f0b4c.aspx](http://www.abb.us/cawp/abbzh254/9cefb344ae2fbf87c1257918002f0b4c.aspx)  
**Established:** 2010  
**Fund Size:** $100 million invested between 2010-2012  
**Investment Amount:** $2-$10 million investments  
**Fund Name:** ABB Technology Ventures  
**Current Portfolio:** 10 investments, investing in 4-6 new companies per year with half of those located in North America.  
**Investment mission:** ATV is focused on bringing together new technologies, new markets and new talent to discover tomorrow's energy solutions and to accelerate the growth of ABB's global power and automation businesses. ATV seeks to “see around corners” and is in constant contact with ABB’s chief technology officer, the technology heads for each of ABB’s five divisions and over 20 business units (BUS), as well as the seven global ABB Corporate Research Centers (CRCs).  
**Investment stage/criteria:** Focus on early- and growth-stage investments in novel companies introducing new technologies and improvements on existing technologies that increase performance, reduce cost or open up new business models or commercial opportunities. Ideal targets have solid intellectual property and product or service prototypes in place. We usually seek minority preferred equity ownership positions and often take board seats.  
**Technology areas of focus:**  
- Energy Infrastructure including areas such as smart grid communications, cyber security, data center optimization software,  
- Cleantech sectors such as wind resource optimization, wave energy technology, clean transportation, and water distribution network optimization.  
**Fund Management:** ATV’s diverse investment team is comprised of ABB veterans with nearly 30 years of experience inside the ABB Group as well as individuals with strong backgrounds in traditional venture capital investing. Girish Nadkarni is the Managing Director and Head of ABB Technology Ventures headquartered in Zurich, Switzerland. Kirt Kaltenegger is Head of Technology in Zurich, Andrew Tang is Managing Director in Silicon Valley, and Grant Allen is Vice President out of Washington D.C.  
**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>12040 Regency Parkway</td>
<td>Cary</td>
<td>NC</td>
<td>27518</td>
<td>United States</td>
<td></td>
</tr>
</tbody>
</table>

**AbbVie Ventures**

**Corporate Arm:** Abbvie  
**Website:** [http://abbviebiotechventures.com](http://abbviebiotechventures.com)  
**Established:** 2013  
**Fund Size:** Unavailable  
**Investment Amount:** Unavailable  
**Fund Name:** AbbVie Biotech Ventures, Inc. (ABVI)  
**Current Portfolio:** Unavailable  
**Investment mission:** AbbVie Biotech Ventures, Inc. (ABVI) is a subsidiary of AbbVie dedicated to making venture capital investments in emerging biotech and pharmaceutical companies. Unlike traditional venture capital firms, ABVI characterizes an investment’s success by its potential to significantly increase AbbVie’s strategic growth, and not solely by its financial return  
**Investment stage/criteria:** ABVI is interested in promising early-stage opportunities with large markets, differentiated competitive advantages, strong intellectual property protection, and viable clinical and reimbursement pathways. ABVI seeks to invest in innovative and leading-edge companies doing
promising work within AbbVie’s current markets, and in other markets that AbbVie may choose to enter in the future.

**Technology areas of focus:**
- Biotech in sectors such as Neuroscience, Immunology, Virology, and Oncology

**Fund Management:** Operating out of North Chicago, ABVI’s team consists of Managing Director, David Donabedian and Director Margarita Chavez

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 N Waukegan Rd</td>
<td>North Chicago</td>
<td>IL</td>
<td>60064</td>
<td>United States</td>
<td>(847) 932-7900</td>
</tr>
</tbody>
</table>

**Aster Capital**

**Corporate Arm:** Alstom and Schneider Electric

**Website:** [http://aster.com/index.php?id=1](http://aster.com/index.php?id=1)

**Established:** 2000

**Fund Size:** Currently investing out of second fund - Aster II - a $140M fund launched in 2010.

**Investment Amount:** Unavailable

**Fund Name:** Aster II

**Current Portfolio:** 9 companies

**Investment mission:** Aster Capital’s mission has been to invest in and support the most innovative start-ups that are working on solutions to change our world. They focus on highly promising companies and teams that have developed superior solutions to solve global challenges in the energy and environment sectors.

**Investment stage/criteria:** Investment Focus is in early stage with a limited amount of funds available for seed and growth stage investments.

**Technology areas of focus:**
- Energy management solutions and energy conservation including: ultracapacitor cells, energy management software, LED products, and wind and solar.
- Environmental technologies including water treatment and green chemicals.

**Fund Management:** Aster Capital is managed by 14 seasoned and dedicated professionals. The team utilizes its strong network within Alstom, Solvay and Schneider Electric to facilitate cooperation and win-win relationships between portfolio companies and the corporate sponsors.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>330 Townsend Street - Suite 104</td>
<td>San Francisco</td>
<td>CA</td>
<td>94107</td>
<td>United States</td>
<td>(415) 800-0328</td>
</tr>
</tbody>
</table>

**AMD Ventures**

**Corporate Arm:** AMD

**Website:** [http://www.amd.com/us/aboutamd/corporate-information/Pages/amdventures.aspx](http://www.amd.com/us/aboutamd/corporate-information/Pages/amdventures.aspx)

**Established:** Unavailable

**Fund Size:** Unavailable

**Investment Amount:** Unavailable

**Current Portfolio:** 7 companies

**Investment mission:** Through AMD Ventures, AMD’s investment program, AMD invests in strategic software and application ecosystem companies that serve large and growing markets.

**Investment stage/criteria:** Anywhere from seed through late stage

**Technology areas of focus:**
- Strategic software in segments such as: non-traditional gaming, server/datacenters, photo editing tools.
Human Computer interfacing including: video conferencing, video immersion software, 3-D video environments.

**Fund Management:** AMD is headed by 7 professions: Managing Directors include Manju Hegde, Keith Witek, and Ray Schuder.

**Address and Contact Information:**

Email/ Contact Page
AMD.Ventures@amd.com

---

**Amgen Ventures**

**Website:** [http://www.amgen.com/partners/amgen_ventures.html](http://www.amgen.com/partners/amgen_ventures.html)

**Established:** 2004

**Fund Size:** $200 million in two funds: Amgen Ventures I, a $100 million fund founded 2004; and Amgen Ventures II, a $100 million fund founded 2012

**Investment Amount:** Typically $3 million to 5 million per company per round, and may invest up to $15 million over the life of the company.

**Fund Name:** Amgen Ventures II

**Current Portfolio:** 13 companies—12 in Amgen Ventures I; one in Amgen Ventures II

**Investment mission:** The fund is designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen's commitment to helping patients by transforming cutting-edge scientific discoveries into novel treatments for serious illness.

**Investment stage/criteria:** Early-stage to early clinical companies developing human therapeutics. While the fund’s focus is primarily in areas of current therapeutic interest to Amgen—which include oncology, inflammation, hematology/nephrology, metabolic disorders, neuroscience and cardiovascular—the fund also seeks novel modalities with potential to address targets in both current and emerging therapeutic areas of interest. We will also review companies developing drug delivery and monitoring devices. They are currently seeking investments in North America, Europe, and the U.K.

**Technology areas of focus:**

- Therapeutic areas of focus for Amgen include: Oncology, Inflammation, Hematology/Nephrology, Metabolic Disorders, Neuroscience and Cardiovascular.

**Fund Management:** The fund is Managed by Mr. Stuart Mackey and Directed by Janis Naeve out of the San Francisco office.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>1120 Veterans Boulevard</td>
<td>San Francisco</td>
<td>CA</td>
<td>94080</td>
<td>United States</td>
</tr>
</tbody>
</table>

---

**Astellas Venture Management**

**Corporate Arm:** Astellas Pharma, Inc.

**Website:** [http://www.astellasventure.com/](http://www.astellasventure.com/)

**Established:** 1999

**Fund Name:**

- Astellas Venture Fund I (AVF I) since 2005
- Fujisawa Investments for Entrepreneurship II (FITE II) since 2001
- Astellas Venture Capital (AVC) since 2000
- Fujisawa Investments for Entrepreneurship (FITE) since 1999

**Current Portfolio:** 19 companies

**Investment mission:** Through its strategic investments in private early-stage companies, the funds aim to forge relationships with Astellas Pharma which may lead to larger collaborations in the future. AVM is
able to provide portfolio companies with invaluable advice and assistance. Astellas philosophy is to “Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.”

**Investment stage/criteria:** relatively early-stage biotechnology companies that have not yet begun testing their products in clinical trials as well as have programs at very early stages of clinical trials.

**Technology areas of focus:**
- Therapeutic areas where there is a high degree of unmet medical needs.

**Fund Management:** Sakae Asanuma acts as President and CEO, Ken Shimokawa acts as Senior Investment Director, Makoto (“Mark”) Ohori acts as Investment Director.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. Box 7585</td>
<td>Menlo Park</td>
<td>CA</td>
<td>94026</td>
<td>United States</td>
</tr>
</tbody>
</table>

**BASF Venture Capital**

**Corporate Arm:** BASF

**Website:** [http://www.basf-vc.de/index.php?id=1&L=1](http://www.basf-vc.de/index.php?id=1&L=1)

**Established:** 2001

**Fund Size:** Not Specified

**Investment Amount:** BASF Venture Capital typically invests between one and five million Euros per venture.

**Fund Name:** BASF Venture Capital fund

**Current Portfolio:** 23 companies

**Investment mission:** The over-riding objective of our investment is to link the strategic and operational interests of BASF Group with innovative technologies of emerging businesses.

**Investment stage/criteria:** Our preference is to get involved with financing in the early stages, after the creation of the company. All potential projects should feature attractive returns and a strong business plan. As well as a solid capital structure we expect to see skilled and highly committed start-up management.

**Technology areas of focus:** Prefer to invest in start-up companies with innovations in chemicals, plastics, functional solutions, agricultural solutions, and oil and gas. Also very interested in new methods and products in:
- Energy management: new materials and technologies to transform, safeguard or store energy
- Energy management: organic electronics for flexible displays, OLED-Lighting, Batteries, Organic photovoltaic (OPV), printable eletronics
- MedTech: surface treatment for medical systems
- Green Biotechnology
- Industrial Biotechnology for new products
- Raw Material Change: sustainable production of chemical intermediates based on renewable resources
- Nanotechnology: material with novel properties and applications

**Fund Management:** BASF Venture Capital is based in Ludwigshafen and has offices in Freemont (California, USA), Boston (USA), Hong Kong (China) and Tokyo (Japan). Its professional investment team is made up of people with financial and various technical backgrounds. The portfolio investments focus on new technologies in areas relevant to BASF (e.g. new materials). Investment Managers include Dr. Claus Hackmann, Björn Heinz, Christoph Köhler, Katharina Mandl, and Dirk Nachtigal among others. Individual contact information available at [http://www.basf-vc.de/index.php?id=20&L=1](http://www.basf-vc.de/index.php?id=20&L=1)

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Gartenweg Gebäude Z 025</td>
<td>Ludwigshafen</td>
<td></td>
<td>67063</td>
<td>Germany</td>
<td>49 621 60 76801</td>
</tr>
</tbody>
</table>
**Baxter Ventures**  
**Corporate Arm:** Baxter International Inc.  
**Website:** [http://www.baxter.com/about_baxter/scientific_excellence/baxter_ventures/](http://www.baxter.com/about_baxter/scientific_excellence/baxter_ventures/)  
**Established:** 2011  
**Fund Size:** $200 million  
**Investment Amount:** A typical equity investment is $1 million to $5 million initial investment, with a potential of investing up to $10 million over the life of the company.  
**Fund Name:** Baxter Ventures  
**Current Portfolio:** Seven investments, most being direct investment in companies, with the rest being investments in life sciences venture funds.  
**Investment mission:** Baxter Ventures identifies companies with promising technologies, products and/or therapies, and provides them with the capital and expertise needed to drive successful innovation. Baxter Ventures was created in 2011 by Baxter International Inc., which has an 80-year legacy of healthcare innovation and saving and sustaining lives worldwide.  
**Investment stage/criteria:** Our focus includes therapeutic areas complementary to those of Baxter’s Medical Products and BioScience businesses, as well as cutting-edge technologies and therapies outside of our current product portfolio that have sustainable long-term growth potential.  
**Technology areas of focus:**  
- Medical Devices including: Fluid Management Systems, Home Care Therapies, Infusion Systems/IV Tubing  
- Pharmaceuticals including: Anesthesia, Immunology/Inflammation, Pulmonology, Regenerative Medicine, Vaccines  
- Protein based Therapeutics  
- Hematology: sickle cell disease  
- Oncology: Solid tumors  
- Immunology: biosimilars  
- Biosurgery, help surgeons stop bleeding, heating up after surgery  
- Devices: drug delivery, IV systems, Dialysis  
- IT for hospital operations, connected to equipment  
- Point of care diagnostics, instant results that nurses can read bedside  
**Fund Management:** Not Available  
**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>One Baxter Parkway</td>
<td>Deerfield</td>
<td>IL</td>
<td>60015-4625</td>
<td>United States</td>
<td>(800)-422-9837</td>
</tr>
</tbody>
</table>

**Bloomberg Ventures**  
**Corporate Arm:** Bloomberg  
**Website:** [http://www.bloombergbeta.com/](http://www.bloombergbeta.com/)  
**Established:** 2013  
**Fund Size:** $75 million fund  
**Investment Amount:** Not Available  
**Fund Name:** Bloomberg Beta  
**Current Portfolio:** Seven investments  
**Investment mission:** Our goal is to expand Bloomberg’s horizons by backing extraordinary entrepreneurs who have something to teach the world.  
**Investment stage/criteria:** Invest at early stages.  
**Technology areas of focus:**
Data
Content Discovery
Media Distribution
Technology Platforms
Networks and Communities
Human-Computer Interaction
Radically New Organizational Models

Fund Management: Not Specified

Address and Contact Information:

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Pier #101</td>
<td>San Francisco</td>
<td>CA</td>
<td>94111</td>
<td>United States</td>
</tr>
</tbody>
</table>

Boehringer Ingelheim Ventures
Corporate Arm: Boehringer Ingelheim
Website: http://www.boehringer-ingelheim-venture.com/
Established: 2010
Fund Size: $130 million
Investment Amount: Opening investments of up to €2 million per venture will be made at the early stage with subsequent staged investments made to align with each venture’s progress, up to a total of €10-15 million per venture over its life.
Fund Name: Boehringer Ingelheim Venture Fund
Current Portfolio: Eight companies and one fund-in-fund investment
Investment mission: Ultimately, our goal is to add value to those companies we invest in, delivering success for them and generating revenues to finance further new investment to benefit patients.
Investment stage/criteria: The Boehringer Ingelheim Venture Fund will be seeking to provide initial investments in seed or series A funding.

Technology areas of focus:
- Next generation vaccines, e.g. T-Cell vaccines
- Address "undrugable" targets, e.g. targets that are poorly amenable to either current NCEs or NBEs
- Next generation NBEs, e.g. cancer immunotherapeutics
- Regenerative medicine
- New platforms for Targets and Biomarkers identification

Fund Management: Managed out of Ingelheim Germany by Vice President Frank Kalkbrenner and Directors Ilka Wicke, Martin Heidecker, and Knut Elbers.

Address and Contact Information:

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Binger Strasse 173</td>
<td>Ingelheim am Rhein</td>
<td></td>
<td>55216</td>
<td>Germany</td>
<td>49 6132 77 8740</td>
</tr>
</tbody>
</table>

Comcast Ventures
Corporate Arm: Comcast Corporation
Website: http://www.comcastventures.com/
Established: 1999
Fund Size: will invest up to $75 million a year from a total fund amounting to $750 million.
Investment Amount: Initial investments typically range in size from $2 million to $15 million.
Fund Name: Comcast Venture Fund
**Current Portfolio:** 78 companies

**Investment mission:** Ultimately, our goal is to add value to those companies we invest in, delivering success for them and generating revenues to finance further new investment to benefit patients.

**Investment stage/criteria:** We will consider investing in promising businesses at any point of development from seed through late stage.

**Technology areas of focus:**
- Advertising including: engines, mobile, video ad management, and TV ad media.
- Enterprise expertise that includes: mobile enterprise platforms, B2B health-information, and security services.
- Infrastructure including: cloud-based network virtualization, data aggregation, and video and voice broadband technologies.

**Fund Management:** Comcast Ventures’ team of venture professionals comes with a diverse range of deep industry experience. We leverage our connections and insights to advise our portfolio companies on strategy, recruiting, business models, fundraising, sales, business development and exits.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
<th>Email/ Contact Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 Geary Street, 10th Floor</td>
<td>San Francisco</td>
<td>CA</td>
<td>94108</td>
<td>United States</td>
<td>(415) 926-5540</td>
<td><a href="mailto:info@comcastventures.com">info@comcastventures.com</a></td>
</tr>
<tr>
<td>480 Cowper Street, Suite 200</td>
<td>Palo Alto</td>
<td>CA</td>
<td>94301</td>
<td>United States</td>
<td>(415) 926-5540</td>
<td><a href="mailto:info@comcastventures.com">info@comcastventures.com</a></td>
</tr>
</tbody>
</table>

**CTV**

**Corporate Arm:** Chevron Technology Ventures  
**Website:** [http://www.chevron.com/ctv/ctvi/](http://www.chevron.com/ctv/ctvi/)

**Established:** 1999  
**Fund Size:** $250 million  
**Investment Amount:** Not Available  
**Current Portfolio:** 24 companies  
**Investment mission:** We identify technology advances that could strengthen our core operations and lead Chevron to new opportunities for growth. We scan the globe for companies with pioneering technologies that can yield strategic and financial value. We also look for firms that could enhance the way Chevron produces and delivers energy. By helping gifted entrepreneurs realize their vision, we also are shaping the future of Chevron.

**Investment stage/criteria:** We can invest in a company at any phase in the development cycle – from providing early-stage seed investment to offering capital for full-scale commercialization.

**Technology areas of focus:**
- Oil and Gas - Fuel processing, hydrocarbon processing, separation, catalysis, advanced exploration, downhole processing and communications, deepwater production and development, heavy oil upgrading, sensors, improved production, fuel additives and lubricants, automated production operations, processing facilities and infrastructure, water management and enhanced oil recovery.
- Emerging /Alternative Energy - Biofuels, energy efficiency and renewable energy technologies including solar, wind & wave/current
- Advanced Materials - Nanotechnologies, advanced ceramics and polymers, specialty chemicals and coatings
- Communications and Networking - Wireless communications and advanced networking infrastructure to support industrial and remote operations
- Information Technologies - Hardware and software innovations

**Fund Management:** Not Available

**Address and Contact Information:** [http://www.chevron.com/ctv/ctvi/investmentteam/](http://www.chevron.com/ctv/ctvi/investmentteam/)
**Dow Venture Capital**  
Corporate Arm: The Dow Chemical Company  
Website: [http://www.dow.com/venture/](http://www.dow.com/venture/)  
Established: 1993  
Fund Size: $350 million  
Investment Amount: Preferred investment: $500,000 to $5,000,000  
Current Portfolio: More than 25 companies  
Investment mission: Dow is focused on pursuing strategic investments that enable and accelerate Dow’s business growth while adding value to our portfolio companies.  
Investment stage/criteria: Dow VC takes an active role in their investments and aim to lead deals or invest alongside strong lead investors in solid teams with defensible, compelling technologies and credible business models across all stages of development – from seed to late stage.  
Technology areas of focus: Four Megatrends  
  - Agricultural  
  - Consumer & Lifestyle: RFID technology, E-commerce software  
  - Infrastructure & Transportation  
Fund Management: The Dow Venture Capital investment team is comprised of experienced individuals who strategically engage with multiple stakeholders — both inside and outside of the company — to identify strategic investments that demonstrate high growth potential, create strategic impact and accelerate Dow's business growth.  
Address and Contact Information:

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
<th>Email/Contact Page</th>
</tr>
</thead>
</table>

**Evonik Corporate Venturing**  
Corporate Arm: Evonik Industries AG  
Established: 2012  
Fund Size: $130 million  
Investment Amount: $5 million per company  
Current Portfolio: 3 Venture Firms  
Investment mission: We’re a strategic investor that actively collaborates with its portfolio companies helping implement the Evonik open innovation strategy and leveraging the strengths of Evonik to drive growth at portfolio companies.  
Investment stage/criteria: We invest in young companies with innovative technology and high growth potential in the field of specialty chemicals, companies with solutions to problems within the following megatrends:  
Technology areas of focus:  
  - Resource efficiency  
  - Health & Nutrition  
  - Globalization  
Address and Contact Information:

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
<th>Email/Contact Page</th>
</tr>
</thead>
</table>
GE Ventures
Corporate Arm: General Electric
Website: [http://www.ge.com/about-us/ge-ventures](http://www.ge.com/about-us/ge-ventures)
Fund Size: More than 30+ startup investments, technology and commercial collaborations in progress.
Investment Amount: $1-$3 Million investments
Fund Name: GE Venture Fund
Investment mission: We are looking for ideas and partners that can advance industries and improve lives. Our goal is to become the global partner of choice to accelerate growth and commercialize innovative ideas that will help make the world work better – to build, power, move and cure.
Investment stage/criteria: Mid-Stage Companies. While historically focused on Series B and C rounds, GE Ventures has expanded participation to include support of accelerators and investing seed and Series A capital.
Technology areas of focus:
- Software: Data & analytics, XaaS, machine to machine automation, cloud and security
- Health: Precision medicine, big data & clinical decision support, life sciences, minimally invasive guidance, patient monitoring & safety
- Energy: Distributed generation, including renewables, smart grid applications, next generation transportation and infrastructure, oil & gas, thermal technologies
- Advanced Manufacturing: Material science, digital fabrication, 3-d printing, additive manufacturing
Fund Management: With offices in the San Francisco Bay area and New York, GE Ventures combines capital, technical and commercial expertise, infrastructure, and the GE global network of businesses and partners to scale great ideas while driving growth for our start-up partners and GE. GE acts as a minority investor with less than 20% ownership.
Address and Contact Information:
[Email/ Contact Page](mailto:connect.geventures@ge.com)

GM Ventures
Corporate Arm: General Motors
Website: [http://www.gmventures.com/](http://www.gmventures.com/)
Established: Founded in 2010
Fund Size: Not Available
Investment Amount: Not Available
Fund Name: GM Venture Fund
Current Portfolio: More than 30+ startup investments, technology and commercial collaborations in progress.
Investment mission: To identify, engage and build relationships with other venture capital firms and innovative companies. Our equity investments deliver innovative technology to the global transportation sector.
Investment stage/criteria: Growth Stage Companies
Technology areas of focus:
- Cleantech- Electric Vehicle fuel cell technology, emission controls, motors, smart grid vehicle energy efficiency technology.
- Infotainment- vehicle HMI, voice recognition, in-vehicle advertising, cloud services, integration of personal devices
• Advanced materials- light-weight materials, eco-friendly materials, materials with phase changing characteristics
• Automotive-related technologies- advanced sensors to enable autonomous driving, safety features, etc.

**Fund Management:** Jon Lauckner was named GM Vice President and Chief Technology Officer (CTO), effective April 1, 2012. In addition to his role as CTO, Jon remains President, GM Ventures and also responsible for leading GM’s Global Research and Development organization. Sherwin Prior was named Managing Director, General Motors Ventures LLC effective September 1, 2010. Anish Patel was appointed Investment Manager, General Motors Ventures LLC effective September 1, 2010.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
<th>Email/Contact Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>300 Renaissance Center</td>
<td>Detroit</td>
<td>MI</td>
<td>48265</td>
<td>United States</td>
<td></td>
<td><a href="mailto:faq@gmventures.com">faq@gmventures.com</a></td>
</tr>
</tbody>
</table>

**Google Ventures**

**Corporate Arm:** Google Inc.

**Website:** [http://www.googleventures.com/](http://www.googleventures.com/)

**Established:** Founded in 2009

**Fund Size:** $200 million

**Investment Amount:** The firm invests up to $250,000 in early stage start-ups.

**Current Portfolio:** Over 150 companies

**Investment mission:** We look for entrepreneurs with a healthy disregard for the impossible. Our team is diverse and so is our appetite for investing — we work with companies in virtually any sector and at any stage of their journey. We invest for financial return. This clear objective keeps us 100% focused on the success of our companies — not on Google’s strategic goals.

**Investment stage/criteria:** Any Stage

**Technology areas of focus:**
- Mobile: advertising, apps, etc.
- Gaming
- Energy: Solar, biofuels, etc.
- Life Sciences: cancer diagnostics, biotech, etc.

**Fund Management:** Google Ventures has offices in Mountain View, New York City and Cambridge. Partners on Google Ventures include Wesley Chan, Joe Kraus, Kevin Rose, Bill Maris, Karim Faris, Krishna Yeshwant, and Rich Miner.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>1600 Amphitheatre Parkway</td>
<td>Mountain View</td>
<td>CA</td>
<td>94043</td>
<td>United States</td>
</tr>
</tbody>
</table>

**Hitachi Corporate Venture Capital Fund**

**Corporate Arm:** Hitachi

**Website:** [http://www.hitachi.co.jp/cvc/e/](http://www.hitachi.co.jp/cvc/e/)

**Established:** Founded in 2000

**Fund Size:** 10 billion-yen investment fund

**Investment Amount:** Not Available

**Fund Name:** Hitachi Corporate Venture Capital Fund (Hitachi CVC Fund)

**Current Portfolio:** Not Available

**Investment mission:** Investment fund to invest in promising technology startup companies that
accelerate the creation of new business opportunities in line with the objectives of Hitachi. Hitachi will build collaborative structures among the venture businesses and provide its own technology, sales networks and business resources to nurture and incubate these ventures. The fund is also preparing for spin-offs innovated within Hitachi itself.

**Investment stage/criteria:** The firm seeks to invest at any stage of a company’s development, including seed stage, first, and later rounds of financing

**Technology areas of focus:**
- Internet technologies, such as these areas of Hitachi’s business: Digital Imaging Systems, ATM & Self Service Terminals (identify verification), LCD Projector, video and wireless networks, e-business, SAN solutions, broadband IP.
- Biotechnology, Hitachi’s products include: Medical Imaging Systems, including MRI, CT, Ultrasound, Optical Topography, Radiography, and X-Ray Systems. Bioinformatics and nanotechnology applications.

**Fund Management:** The fund is managed by the CVC Office. Shigemichi Matsuka, Executive Vice President and Director, is the general manager of the office. In the U.S., Hitachi America*, Ltd., Hitachi’s subsidiary company in North America, is setting up a new office, the U.S. CVC Center headed by Dr. Kenji Takeda, Senior Vice President and Chief Technology Officer of Hitachi America. Additional staff: Mr. David Ai, Vice President; Ms. Vinie Zhang, Vice President; Ms. Christina Boozer, Executive Administrator.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>750 Central Expressway MS 3201</td>
<td>Santa Clara</td>
<td>CA</td>
<td>95050-2627</td>
<td>United States</td>
<td>408-970-7138</td>
</tr>
</tbody>
</table>

---

**Intel Capital**

**Corporate Arm:** Intel

**Website:** [http://www.intelcapital.com/](http://www.intelcapital.com/)

**Established:** 1991

**Fund Size:** Since 1991, Intel Capital has invested more than US$10.8 billion in over 1,276 companies in 54 countries. New $300 million ultra-book fund newly launched.

**Investment Amount** Not Available

**Current Portfolio:** Over 300 companies

**Investment mission:** Our mission is to invest across the broad spectrum of technology innovation to encourage the creation of the technologies of tomorrow. We focus on helping entrepreneurs scale from start-up to global corporation. Our technology expertise, brand capital, and access to our global network via our business development programs help Intel Capital entrepreneurs build lasting success.

**Technology areas of focus:**
- Consumer Internet: Social media, web-platforms, etc.
- Digital Media & Entertainment: social games, social media, media solutions, etc.
- Mobility: Antenna & RF solutions, audio technology, handsets, tablets, laptops, consumer technologies, etc.
- Software & Services: Cloud Computing, In-app marketing, Applications, Management Software, etc.

**Fund Management:** Our commitment to offering strategic guidance and adding value beyond the monies we invest sets Intel Capital apart. Our investment, business development and M&A professionals make this possible. These individuals span the globe and specialize in various industries.

Arvind Sodhani is president of Intel Capital. Sodhani was elected vice president by the board of directors in May 1990, served as senior vice president from 2005 to 2007 and was promoted to executive vice president in December 2007.
Johnson & Johnson Development Corporation
Parent: Johnson & Johnson
Website: http://www.jjdevcorp.com/
Established: 1973
Fund Size: Not Available
Investment Amount: The fund amount of a venture investment varies from a few hundred thousand dollars to millions and depends upon the stage of funding, phase of product development, and alignment of the business venture with JJDC strategic growth objectives.
Current Portfolio: Not Available
Investment mission: Johnson & Johnson Development Corporation creates strategic growth options for Johnson & Johnson by investing in emerging health care businesses.
Investment stage/criteria: Johnson & Johnson Development Corporation’s (JJDC) investments range from the early stages of seed funding to the advanced stages of series venture management. JJDC investments have stringent selection criteria and are supported with validated data and research. JJDC is interested in venture business opportunities that have large addressable markets, clear competitive advantages, IP protection, an executable clinical and commercialization plan, which are led by experienced management.
Technology areas of focus:
- Medical Devices & Diagnostics
- Pharmaceuticals & Biotechnology
- Consumer Products
Fund Management: JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson. J&J, in 2012, opened an incubator within their corporate research operations in San Diego.

Lilly Asia Ventures
Parent: Eli Lilly and Company
Website: http://www.lillyasiaventures.com/en/
Established: 2008
Fund Size: $100 million
Investment Amount: $5 million to $15 million per company
Current Portfolio: 11 companies
Investment mission: We seek companies that are going rapidly and emerging as market leaders, as well as those that are developing innovative products with significant impact on medical care in China and around the world.
Investment stage/criteria: The most typical stage of our investment is growth stage, though we have also invested in early stage and pre-IPO opportunities. Focus on companies with potential to be top-ranked in its category in China, whether a drugmaker or pharmaceutical service provider, and potential
to conduct business outside China

**Technology areas of focus:**
- Human therapeutics – pharmaceuticals and biotechnology (this is our primary focus)
- Medical technology – devices and diagnostics
- Healthcare services – hospitals, clinics, etc.
- Animal health
- Broader life sciences – industrial biotechnology, agricultural biotechnology, nutraceuticals

**Fund Management:** Based in Shanghai, Yi Shi oversees Lilly Asia Ventures since its founding in 2008. Prior to his current role, Yi worked at Eli Lily and Company with a diverse set of experiences including venture start-up, marketing, business development licensing, and corporate strategy. Currently, he serves on the Board of HD Bioscience, Chipscreen, Beta Pharma, BrightGene Biomedical, Novast, and SinqiPharma.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 1504, 1 Corporate Avenue</td>
<td>Shanghai</td>
<td></td>
<td>200021</td>
<td>China</td>
<td>+86 21 6340 6188</td>
</tr>
</tbody>
</table>

**Lilly Ventures**

**Parent:** Eli Lilly and Company  
**Website:** http://lillyventures.com/  
**Established:** 2001  
**Fund Size:** $200 million  
**Investment Amount:** $5 million to $15 million per company  
**Current Portfolio:** 15 companies  
**Investment mission:** Our investment philosophy drives us to seek great companies with compelling life science innovations. We partner actively with the management teams of our portfolio companies to realize the potential of their technologies.

**Investment stage/criteria:** Seeking biotech companies that leverage proprietary drug discovery or development technologies to build a multi-product pipeline; companies focused on the convergence of devices with pharmaceuticals or diagnostics; North American and European regions

**Technology areas of focus:**
- Human therapeutics – pharmaceuticals and biotechnology (this is our primary focus)
- Medical technology – devices and diagnostics
- Healthcare services – hospitals, clinics, etc.
- Animal health
- Broader life sciences – industrial biotechnology, agricultural biotechnology, nutraceuticals

**Fund Management:**
- Office Manager, Lisa Belas: lisa@lillyventures.com  
- Venture Partner, Steve Hall: steve@lillyventures.com  
- Managing Director, Ed Torres: ed@lillyventures.com

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>115 W. Washington Street Suite 1680</td>
<td>Indianapolis</td>
<td>IN</td>
<td>46204</td>
<td>USA</td>
<td>(317) 429-0140</td>
</tr>
</tbody>
</table>

**Merck Research Venture Fund**

**Corporate Arm:** Merck  
**Website:** http://www.merck.com/licensing/our-partnership/Flagship-Ventures-partnership.html  
**Established:** 2011
**Fund Size:** $250 million fund, 80% invested in other funds (Flagship, East Coast, West Coast, and China fund), 20% in direct company investments.

**Investment Amount:** Not Specified

**Current Portfolio:** Not Available

**Investment mission:** The Merck Research Ventures Fund is an investment vehicle through which Merck will help to shape the diversity and quality of external innovation, which may be captured through future partnerships and acquisitions. MRVF is jointly governed by an Investment Committee and a Scientific Management Approval Committee, each made up of senior Merck employees.

**Investment stage/criteria:** Early Stage

**Technology areas of focus:**
- Life Sciences: not specified

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Phone</th>
<th>Email/ Contact Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>781-684-0770</td>
<td><a href="mailto:flagship@schwartzmsl.com">flagship@schwartzmsl.com</a></td>
</tr>
</tbody>
</table>

---

**Morgan Stanley Venture Partners**

**Corporate Arm:** Morgan Stanley


**Established:** 1986

**Fund Size:** Not Specified. Expansion Capital has invested over $1.1 billion of growth capital in over 150 companies.

**Investment Amount:** $5 – 15 million minority, private equity investments

**Fund Name:** Morgan Stanley Expansion Capital

**Current Portfolio:** 14 Companies

**Investment mission:** From the time of a potential investment, we pursue a value-creation strategy that is focused on both financial and operational measures. We aim to provide valuable advice and guidance to our portfolio companies, particularly regarding financing, capital structure, strategy and operational improvements, recruiting, and exit opportunities.

**Investment stage/criteria:** later-stage, private emerging growth companies in technology and other high growth sectors including healthcare, consumer and digital media.

**Technology areas of focus:**
- Technology: software, wireless networking, etc.
- Healthcare: pharmaceuticals, molecular diagnostics, etc.
- Consumer: E-commerce and data management solutions
- Digital Media: Video Streaming and Content Management,

**Fund Management:** Our investment team brings a depth of experience partnering with entrepreneurial management teams to help develop and scale their businesses as well as leveraging the Morgan Stanley network to benefit our portfolio.

- Managing Director- Pete Chung
- Managing Principal- Melissa Daniels
- Managing Principal- Lincoln Isetta

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
<th>Email/ Contact Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>555 California Street 14th Floor</td>
<td>San Francisco</td>
<td>CA</td>
<td>94104</td>
<td>United States</td>
<td>(415) 576-2000</td>
<td><a href="mailto:expansion.capital@morganstanley.com">expansion.capital@morganstanley.com</a></td>
</tr>
<tr>
<td>1585 Broadway 39th Floor</td>
<td>New York</td>
<td>NY</td>
<td>10036</td>
<td>United States</td>
<td></td>
<td><a href="mailto:expansion.capital@morganstanley.com">expansion.capital@morganstanley.com</a></td>
</tr>
</tbody>
</table>

---

**Motorola Solutions Venture Capital**

**Corporate Arm:** Motorola
**Motorola Solutions Venture Capital**

**Established**: 1999  
**Fund Size**: Not Available  
**Investment Amount**: between $1 million and $5 million  
**Current Portfolio**: 22 companies  
**Investment mission**: To bring together new technologies, new markets and new talent to discover and invest in tomorrow's technology solutions. Every investment we make is a strategic alliance encapsulated by vision, creativity, and business acumen.  
**Investment stage/criteria**: Early to Late Stage  
**Technology areas of focus**:  
- Telecommunications, Information Technology/Enterprise and Government and Public Safety including mobile computing, video analytics, retail experience analytics, RFID-enabled solutions and security.

**Fund Management**: The Motorola Solutions Venture Capital team is responsible for identifying and investing in new technologies that strategically and financially benefit Motorola Solutions.  
- Managing Director- Reese Schroeder  
- Managing Director- Tony Palcheck  
- Investment Manager- Mel Gaceta

**Address and Contact Information**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>1303 East Algonquin Road</td>
<td>Schaumburg</td>
<td>IL</td>
<td>60196</td>
<td>United States</td>
<td>(847)-576-5000</td>
</tr>
</tbody>
</table>

**Panasonic Venture Group**

**Corporate Arm**: Panasonic  
**Website**: http://www.panasonicventures.com/  
**Established**: 1998  
**Fund Size**: Not Available  
**Investment Amount**: in the range of $1 to 3 million for companies that have a demonstrated, proven technology and typically at post-A rounds of funding.  
**Current Portfolio**: 22 companies  
**Investment mission**: New ideas are necessary to spur growth in any successful corporation. To complement Panasonic's internal innovation goals, the Venture Group sources venture-backed start-ups with compelling technologies that align with Panasonic's innovation strategies. With visions aligned, the Venture Group makes investments that support strategic relationships between Panasonic and our portfolio companies, with the ultimate goal of enhancing value for our customers.  
**Investment stage/criteria**: We seek investment and partnering candidate companies once they have been organized as an independent C-Corp, have a business plan, and have developed their innovation to the point that it can be demonstrated at least in a lab environment. Most our investments are post-A rounds.  
**Technology areas of focus**:  
- Compelling technologies in the areas of home networking, semiconductors, reconfigurable processors, digital content, security, printed electronics, optics and other areas.

**Fund Management**:  
- Hiroshi Miyajima, Deputy Director  
- Patrick Suel, Venture Partner  
- Ira Nydick, Technology Partner
Pereg Venture

**Corporate Arm:** Nielsen  
**Website:** [http://www.peregventures.com/home.html](http://www.peregventures.com/home.html)  
**Established:** 2012  
**Fund Size:** Not Available  
**Investment Amount:** Nielsen’s investment commitment is conditioned on the fund obtaining total investment commitments of not less than $25 million, which is planned for the first half of 2013.  
**Current Portfolio:** Not Available

**Investment mission:** We invest in entrepreneurs with ambitious ideas that will transform the way we market. But we understand that new businesses need so much more – our entrepreneurial managers, our strategic investors and our exceptional community of advisers, give entrepreneurs access to insights and experience that can help them build their businesses.

**Investment stage/criteria:** invest in early stage, high-growth, transformational technologies

**Technology areas of focus:**
- Market intelligence – intimately understanding the factors that influence consumers
- Management technologies – finding smarter ways to manage advertising spend and projects
- Mobile enablers – enabling marketing to an increasingly mobile world
- Online enablers – reaching and appealing to online consumers
- Advertising solutions – using new mediums to appeal to buyers

**Fund Management:**
- Itzhak Fisher- will serve as chairman and partner of Pereg Ventures. As executive vice president of Global Business Development for Nielsen, Fisher leverages three decades of mergers, acquisitions and initial public offerings and has responsibility for strategic business development initiatives and mergers and acquisitions that enhance Nielsen’s capabilities and address clients' priorities.
- Claudia Iannazzo, Pereg Ventures CEO and partner, has facilitated more than $10 billion of acquisitions, divestments, IPOs, alliances and partnerships for public companies and new ventures around the globe. She has led strategic alliancing, acquisition and turnaround activities for two Australian advertising giants, Tabcorp Holdings (Australia's largest gaming, entertainment and hospitality company) and Foster’s Group (Australia's leading brewer and winemaker), and headed commercial functions within multinational technology companies Infosys Technologies and BAE Systems.

---

Pfizer Venture Investments

**Corporate Arm:** Pfizer  
**Established:** 2004  
**Fund Size:** Not Available

**Investment Amount:** With a $50M annual budget for private investments, PVI may invest $5-$10M per round in selected companies in any stage of development, with a strong focus on growth stage opportunities.
Current Portfolio: 25 Companies
Investment mission: Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development, and Innovation division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry.
Investment stage/criteria: will consider companies at all stages of development, including start-ups, spinouts, and consortia investments.
Technology areas of focus:
- Therapeutics
- Platform technologies
- Diagnostics
- Drug delivery
- Pharmaceutical Services
- Healthcare IT
Fund Management:
- Bill Burkoth- currently a Senior Director on the Pfizer's Venture Investments Team. Since joining Pfizer in early 2004, he has played an instrumental role in numerous new Pfizer venture investments. Bill currently serves as a director of DVS Sciences and Novocure, and as a board observer of Avid Radiopharmaceuticals, Evolution Benefits, HD Biosciences, M2S, and Nodality.
- Barbara J. Dalton, Ph.D. currently Director, joined Pfizer in 2007 to manage the Pfizer Ventures Investments team within the Worldwide Business Development organization. She is responsible for growing their corporate venture activities, managing the corporation's private equity portfolio, advising on structured equity transactions and driving novel transactions to achieve corporate objectives.

Samsung Ventures
Corporate Arm: Samsung
Website: http://www.samsungventures.com/
Established: 1999
Fund Size: Not Available
Investment Amount: Not available
Current Portfolio: Over 100 companies
Investment mission: Samsung Venture Investment Corporation was established to promote establishment of promising small and medium-sized companies engaging in developing new and sophisticated technologies based on managerial know-how and trust. It also contributes to the national economic development and solidification of industrial structure and to the development of domestic venture companies by introducing advanced investment techniques.
Investment stage/criteria: Potential Investment subjects range from start-ups to established companies that are about to be listed in the stock market. Prefer to play early.
Technology areas of focus:
- Semiconductors
- Telecommunication
- Software
- Internet
- Bio engineering
• Medical Industry
• Film/Video Industry

Address and Contact Information:

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>75 W. Plumeria Drive</td>
<td>San Jose</td>
<td>CA</td>
<td>95134</td>
<td>United States</td>
</tr>
</tbody>
</table>

**SR One (GlaxoSmithKline)**
Corporate Arm: GlaxoSmithKline
Website: [http://www.srone.com/](http://www.srone.com/)
Established: Founded in 1985
Fund Size: $30 million to $50 million in five or six companies a year; more than $680 million invested since 1985
Fund Name: SR One
Current Portfolio: 31 private and public companies
Investment mission: The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Their expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries. Overall, they look for investments that can provide attractive financial returns and significant strategic value.
Investment stage/criteria: Early Stage healthcare companies pursuing innovative, breakthrough science. They prefer to be the lead or co-lead investor. They will also actively participate in opportunities as part of a syndicate. They are aligned with other financial investors and do not ask for specific product rights or options. They are active investors and typically take board of directors or board observer seats. They also maintain a strict firewall with GSK on confidential items received from a portfolio company or an investment opportunity under review by our team.
Technology areas of focus:
• Modern Therapeutic Healthcare including areas such as: gene therapies, computer vision technology, pharmaceuticals, vaccines, bone fixation, stem cells, DNA repair, and neuroscience solutions.

**Fund Management:** The Fund is managed from four locations including Pennsylvania, London, San Francisco, and headquartered in Cambridge Massachusetts. The President Jens Eckstein, heads the Cambridge office.

**Takeda Ventures Inc.**
Corporate Arm: Takeda Pharmaceutical Company
Website: [http://www.takedaventures.com/](http://www.takedaventures.com/)
Established: 2001
Investment Amount: Not Specified
Current Portfolio: 13 Companies
Investment mission: To identify, help create and support the development of therapeutic innovation that aligns with Takeda’s own strategic imperatives. We do this by investing in technology and product concepts, and highly effective teams that can turn ideas into reality. Our primary focus is on medium to longer term returns in the form of product and technology successes for our portfolio companies and capital gains for the financial institutions we work with. As a Pharma strategic investor, TVI aims to...
provide support and guidance to entrepreneurs and early-stage companies driving concepts from preclinical through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda’s considerable R&D resources.

**Investment stage/criteria:** focus is on start-up/seed rounds, through mid-stage financings. We consider follow-on rounds of investment where they assist in driving promising projects to fruition, and strategic alignment of the investment remains true.

**Technology areas of focus:**
- Therapeutics- concentrating on drugs an biotherapeutics to treat cancer, metabolic disorders, cardiovascular disorders, chronic inflammatory and immune disorders and diseases for the central nervous system.

**Fund Management:**
- Graeme Martin, Dr. Martin is President and CEO of Takeda Ventures, Inc, with day-to-day responsibility for operations. He brings more than 30 years R&D experience in large Pharma as well as Biotech, and was responsible for three IND submissions one of which led to the launch of Zomig® now marketed worldwide for the acute treatment of migraine. Dr Martin joined TVI in 2003, and has been responsible for building a portfolio of strategic investments representing more than US$45MM under management.
- Yuji Iizawa D.V.M., Ph.D., Dr. Iizawa joined TVI as Vice President in April 2011 with more than 28 years R&D experience at Takeda. Prior to joining TVI, he was Senior Director of Strategic Research Planning Department and Global Research Management Department in Pharmaceutical Research Division, with responsibility for the strategic oversight of Takeda research affiliates Worldwide.

**Address and Contact Information:**

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>ZIP</th>
<th>Country</th>
<th>Phone</th>
<th>Email/ Contact Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>435 Tasso Street, Suite 300</td>
<td>Palo Alto</td>
<td>CA</td>
<td>94301</td>
<td></td>
<td>(650) 328 2900</td>
<td><a href="mailto:contact@tri-takeda.com">contact@tri-takeda.com</a></td>
</tr>
</tbody>
</table>
